GeneSegues Therapeutics is a biopharmaceutical company specializing in the innovation of DNA and RNAi cancer therapeutics, delivered with proprietary sub-50 nanometer (s50) nanocapsule technology. The companys lead product is GS-10, an s50-encapsulated RNAi therapeutic for the treatment of a range of solid tumor cancers including head and neck, prostate and breast and their related metastases. The firm is developing the next generation of targeted drugs for treatment of cancer and other diseases caused by the overproduction of a protein by combining innovative RNAi therapeutics with novel sub-50 nanometer capsule technology that increases the amount of RNAi drug delivered to both primary and metastatic tumors. At 20 nanometers in diameter, s50 nanocapsules are three times smaller than conventional targeted nanoparticles, allowing them to reach and attack cancerous cells where other targeted technologies cannot. This smaller size was engineered without loss of functionality. Thus, in addition to the capability to reach micro-tumors, s50 nanocapsules have active tumor targeting and high payloads of drug in each nanocapsule.
